Abstract:Subsequently to the publication of the above article, and a Corrigendum that has already been published with the intention of showing corrected versions of Figs. 1 and 8 (DOI: 10.3892/or.2022.8348; published online on June 14, 2022), the authors have belatedly realized that the revisions made to Fig. 8 necessitated changes that should have been introduced into Fig. 9, although these were not attended to in the first corrigendum. Essentially, Fig. 8 was revised as the cell apoptosis and cell proliferation assays therein were poorly presented, which made the interpretation of the data difficult; Fig. 9 showed the fractions of apoptotic cells in the SKM‑1 and THP‑1 cell lines with lncENST00000444102 overexpression as this pertained to Fig. 8. A revised version of Fig. 9, presenting the analysis of the data shown in the revised version of Fig. 8, is shown opposite. In addition to the revision of Fig. 9, the sentence starting on p. 517, left‑hand column, line 12 [“The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.001, Fig. 9)”] should be replaced with the following text, to reflect the change in the level of statistical significance: ‘The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.01, Fig. 9)”. Note that the revisions made to Figs. 8 and 9 in this paper have not had a major impact on the reported results, and do not affect the overall conclusions reported in the study. All the authors agree to the publication of this corrigendum. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this additional Corrigendum; furthermore, they apologize for any inconvenience caused to the readership of the Journal. [Oncology Reports 42: 509‑520, 2019; DOI: 10.3892/or.2019.7175]

Corrigendum: NDRG1 Inhibition Sensitizes Osteosarcoma Cells to Combretastatin A-4 Through Targeting Autophagy

[Corrigendum] Enhanced antitumor activity by the combination of dasatinib and combretastatin A‐4 in vitro and in vivo

NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy

Corrigendum: Combination of Rapamycin and MK-2206 Induced Cell Death Via Autophagy and Necroptosis in MYCN-amplified Neuroblastoma Cell Lines.

[Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple‐negative breast cancer through the regulation of pyroptosis

[Corrigendum] Nucleosome‐binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2‐OS osteosarcoma cell lines

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]

Corrigendum to “inhibition of IGF1R Enhances 2-Deoxyglucose in the Treatment of Non-Small Cell Lung Cancer” [lung Cancer 123 (2018) 36–43]

Corrigendum: Inhibition of O-GlcNAc Transferase Sensitizes Prostate Cancer Cells to Docetaxel

[Corrigendum] Hsp90 inhibitor 17‑AAG inhibits stem cell‑like properties and chemoresistance in osteosarcoma cells via the Hedgehog signaling pathway

[Corrigendum] Role of 4‑aminobutyrate Aminotransferase (ABAT) and the Lncrna Co‑expression Network in the Development of Myelodysplastic Syndrome

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum to ‘silencing KIF18B Enhances Radiosensitivity: Identification of a Promising Therapeutic Target in Sarcoma’ [ebiomedicine 61 (2020) 103,056]

[Corrigendum] HORMAD1 Promotes Docetaxel Resistance in Triple Negative Breast Cancer by Enhancing DNA Damage Tolerance

Erratum: BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor: Erratum.

Erratum: Author correction to "The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway" [Acta Pharm Sin B 12 (2022) 1288-1304].

Corrigendum To: NGF Protects Neuroblastoma Cells Against Β‐amyloid Induced Apoptosis Via the Nrf2/HO‐1 Pathway

Erratum: Corrigendum: Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy

[Corrigendum] Tripartite motif‐containing 11 regulates the proliferation and apoptosis of breast cancer cells

[Corrigendum] Exogenous Hydrogen Sulfide Exerts Proliferation, Anti-Apoptosis, Migration Effects and Accelerates Cell Cycle Progression in Multiple Myeloma Cells Via Activating the Akt Pathway

[Corrigendum] The cranberry flavonoids PAC DP‑9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells